| Literature DB >> 34943106 |
Kouadio Ibrahime Sinan1, Uğur Akpulat2, Afaf A Aldahish3, Yasemin Celik Altunoglu4, Mehmet Cengiz Baloğlu4, Dimitrina Zheleva-Dimitrova5, Reneta Gevrenova5, Devina Lobine6, Mohamad Fawzi Mahomoodally6, Ouattara Katinan Etienne7, Gokhan Zengin1, Shafi Mahmud8, Raffaele Capasso9.
Abstract
Boerhavia diffusa is a great tropical plant and is widely used for various traditional purposes. In the present study, we examined the influence of solvents (dichloromethane, ethyl acetate, methanol and infusion (water)) on chemical composition and biological capabilities of B. diffusa. An UHPLC-HRMS method was used to determine the chemical characterization. The biological ability was examined for antioxidant, enzyme inhibitory and anti-cancer effects. To evaluate antioxidant effects, different chemical methods (ABTS, DPPH, CUPRAC, FRAP, metal chelating and phosphomolybdenum) were applied. With regard to enzyme inhibitory properties, cholinesterases, amylase, glucosidase and tyrosinase were used. The MDA-MB-231 breast cancer cell line was chosen to determine anticancer activity. Based on the UHPLC-HRMS analysis, 37 specialized metabolites were dereplicated and identified in the studied extracts. Results revealed the presence of 15 hydroxybenzoic, hydroxycinnamic, acylquinic acids, and their glycosides, one rotenoid, seven flavonoids, 12 fatty acids and two other glycosides. Among the tested extracts, the methanol extract showed a stronger antioxidant ability compared with other extracts. The methanol extract also showed the best inhibitory effects on tyrosinase and glucosidase. In the anti-cancer evaluation, the methanol extract showed stronger anticancer effects compared with water extract. In summary, our observations can contribute to the establishment of B. diffusa as a potential candidate for functional applications in the preparation.Entities:
Keywords: Boerhavia diffusa; anti-cancer; antioxidant; enzyme inhibition; flavonoids; functional applications
Year: 2021 PMID: 34943106 PMCID: PMC8698501 DOI: 10.3390/antiox10122003
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Total phenolic and flavonoids contents of tested extracts. GAE: Gallic acid equivalent; RE: Rutin equivalent. a–d bar wise values with same superscripts of this type indicate no significant difference among extracts (p > 0.05).
Figure 2Total ion chromatograms (TIC) in negative ion mode of the studied Boerhaavia extracts; A-Ethyl acetate extract; B-MeOH extract; C-Dichloromethane extract; D-Infusion with water. For peaks annotation see Table 1.
Figure 3Structure of the bioactive metabolites, found in the studied Boerhaavia extracts; glc = glucose, gal = galactose; rut = rutinose.
Specialized metabolites in Boerhaavia extracts.
| No. | Identified/Tentatively Annotated Compound | Molecular Formula | Exact Mass | Fragmentation Pattern in (−) ESI-MS/MS | tR | Δ ppm | Distribution |
|---|---|---|---|---|---|---|---|
| Hydroxybenzoic, Hydroxycinnamic, Acylquinic Acids, and Derivatives | |||||||
| 1 | protocatechuic acid a | C7H6O4 | 153.0179 | 153.0179 (17.87), 109.0278 (100) | 2.01 | −3.554 | 1, 2, 3, 4 |
| 2 | gentisic acid a | C7H6O4 | 153.0178 | 153.0179 (78.01), 135.0071 (28.94), 109.0278 (100) | 4.98 | -3.554 | 1, 2, 3, 4 |
| 3 | vanillic acid a | C8H8O4 | 167.0343 | 167.0343 (10.91), 152.0103 (100), 123.0154 (14.81), 95.0123 (9) | 7.02 | −3.903 | 1, 2 |
| 4 | caffeic acid a | C9H8O4 | 179.0337 | 179.0337 (17.89), 135.0435 (100) | 4.79 | −0.105 | 2, 3, 4 |
| 5 | quinic acid | C7H12O6 | 191.0548 | 19.0548 (100), 173.0445 (1.81), 127.0384 (4.14), 85.0277 (22.37) | 4.36 | −6.811 | 1, 2, 3, 4 |
| 6 | ferulic acid a | C10H10O4 | 193.0501 | 193.0501 (19.29), 178.0263 (67.83), 149.0597 (20.28), 134.0360 (100) | 5.77 | −2.061 | 1, 2, 3, 4 |
| 7 | isoferulic acid | C10H10O4 | 193.0493 | 193.0493 (100), 178.0260 (3.09), 161.0230 (17.21), 134.0360 (7.30) | 11.50 | 0.055 | 1, 2, 3, 4 |
| 8 | gentisic acid-O-hexoside | C13H16O9 | 315.0721 | 315.0721 (40.05), 153.0178 (74.49), 135.0072 (4.35), 109.0278 (100), 101.02281 (1.44), 65.0380 (7.62) | 2.89 | −0.144 | 1, 2, 3, 4 |
| 9 | chlorogenic (5-caffeoylquinic) acid a | C16H18O9 | 353.0887 | 353.0887 (2.42), 191.0553 (100), 85.0280 (7.41) | 4.45 | 2.676 | 2, 3, 4 |
| 10 | 4-caffeoylquinic acid | C16H18O9 | 353.0874 | 353.0874 (30.06), 191.0558 (43.79), 179.0339 (69.67), 173.0445 (100), 135.0439 (58.77), 93.0331 (20.06) | 4.79 | −1.148 | 1, 2, 3, 4 |
| 11 | ferulic acid 4- | C16H20O9 | 355.1039 | 193.0499 (100), 178.0264 (15.78), 149.0599 (9.40), 134.0361 (36.33) | 5.74 | 1.280 | 1, 2, 3 |
| 12 | syringic acid O-hexoside | C15H20O10 | 359.0974 | 359.0974 (6.71), 197.0449 (100), 182.0217 (19.01), 166.9986 (4.32), 153.0549 (15.22), 138.0309 (29.18), 123.0073 (25.01) | 2.50 | −2.673 | 2, 3, 4 |
| 13 | 3,4-dicaffeoylquinic acid a | C25H24O12 | 515.1185 | 515.1185 (100), 353.0859 (7.33), 191.0554 (30.60), 179.0342 (66.02), 173.0450 (68.67), 161.0232 (8.19), 135.0437 (76.89), 93.0331 (10.24) | 11.13 | −1.882 | 1, 2, 3, 4 |
| 14 | 3,5-dicaffeoylquinic acid | C25H24O12 | 515.1179 | 515.1179 (10.48), 353.0880 (93.64), 191.0552 (100), 179.0340 (52.64), 135.0438 (56.36), 85.0282 (5.71) | 11.40 | −3.182 | 1, 2, 3, 4 |
| 15 | 4,5-dicaffeoylquinic acid | C25H24O12 | 515.1198 | 515.1198 (94.76), 353.0877 (51.76), 191.0554 (25.47), 179.0340 (58.14), 173.0445 (100), 161.0237 (4.88), 135.0438 (68.35), 93.0331 (21.78) | 12.58 | 0.487 | 1, 2, 3, 4 |
|
| |||||||
| 16 | boeravinone B | C17H12O4 | 311.0559 | 311.0559 (100), 283.0600 (6.92), 265.0504 (16.52), 237.0547 (4.88), 209.0599 (5.36), 147.0436 (4.22), 133.0278 (10.06), 109.0279 (3.63) | 17.02 | 0.925 | 2 |
|
| |||||||
| 17 | eupalitin | C17H14O7 | 329.0664 | 329.0664 (74.08), 314.0430 (100), 299.0194 (37.46), 271.0247 (49.23), 199.1331 (3.16), 171.0431 (0.82), 151.0024 (0.84), 112.9837 (3.08) | 22.85 | −0.717 | 1, 2, 3, 4 |
| 18 | Isovitexin a | C21H20O10 | 431.0984 | 431.0984 (100), 341.0669 (30.19), 311.0559 (70.53), 283.0606 (23.32), 269.0445 (2.52), 239.0713 (1.82), 183.5785 (1.14), 161.0237 (1.43), 117.0330 (8.93) | 9.61 | 0.116 | 1, 2, 3, 4 |
| 19 | kaempferol 3- | C21H20O11 | 447.0925 | 447.0925 (100), 285.0381 (18.27), 284.0320 (56.91), 255.0296 (35.53), 227.0334 (24.93), 177.3569 (4.09) | 10.75 | −1.755 | 2, 3 |
| 20 | Isoquercitrin a | C21H20O12 | 463.0873 | 463.0873 (100), 301.0346 (38.07), 300.0271 (81.06), 271.0245 (41.29), 255.0289 (14.51), 227.0339 (2.46), 151.0019 (7.54), 107.0116 (1.86) | 9.51 | −1.855 | 1, 2, 3, 4 |
| 21 | Hyperoside a | C21H20O12 | 463.0877 | 463.0877 (100), 301.0346 (42.87), 300.0271 (80.57), 271.0247 (39.22), 255.0289 (14.90), 227.0333 (1.55), 151.0018 (6.40), 107.0124 (1.25) | 9.82 | −1.121 | 1, 2, 3, 4 |
| 22 | kaempferol-3- | C27H30O15 | 593.1507 | 593.1507 (100), 284.0320 (65.84), 285.0381 (29.78), 255.0290 (34.66), 227.0344 (23.68), 117.0336 (3.60) | 10.33 | −0.832 | 2, 3, 4 |
| 23 | Rutin a | C27H30O16 | 609.1476 | 609.1476 (100), 301.0348 (40.88), 300.0273 (59.06), 271.0248 (34.49), 255.0296 (17.07), 151.0020 (6.31), 107.0120 (1.65) | 9.55 | −0.390 | 1, 2, 3 |
|
| |||||||
| 24 | azelaic acid | C9H16O4 | 187.0965 | 187.0965 (45.53), 141.8659 (1.28), 125.0958 (100), 123.0799 (3.96), 97.0643 (6.19) | 11.66 | −5.731 | 1, 2, 3, 4 |
| 25 | dodecenedioic acid (traumatic acid) | C12H20O4 | 227.1286 | 227.1286 (8.77), 183.1382 (100), 165.1273 (16.47) | 20.33 | −1.375 | 2, 3, 4 |
| 26 | 13-hydroxy-9,11-octadecadienoic acid | C18H32O3 | 295.2279 | 295.2279 (100), 277.2174 (17.71), 195.1384 (18.61), 113.0958 (1.43) | 28.67 | 0.142 | 1, 2, 3, 4 |
| 27 | 9-hydroxy-?-octadecenoic acid | C18H34O3 | 297.2435 | 297.2435 (100), 279.2329 (7.28), 155.1070 (12.75) | 29.81 | −0.162 | 2, 4 |
| 28 | 15-hydroxy-9-oxo-10,12,14-octadecatrienoic acid | C18H26O4 | 305.1761 | 305.1761 (93.79), 287.1661 (7.98), 249.1497 (68.78), 205.1595 (8.20), 185.1176 (2.64), 135.0803 (100), 125.0959 (22.92) | 24.58 | 1.335 | 2, 3, 4 |
| 29 | 14-hydroxy-9-oxo-11,13,15-octadecatrienoic acid | C18H28O4 | 307.1918 | 307.1918 (100), 289.1797 (9.94), 197.1184 (14.02), 185.1176 (69.09), 109.0646 (5.04) | 21.35 | 1.131 | 1, 2, 3, 4 |
| 30 | 14-hydroxy-9-oxo-11,13,15-octadecatrienoic acid | C18H28O4 | 307.1915 | 307.1915 (25.91), 289.1819 (17.24), 235.1335 (100), 211.1334 (32.15), 209.1172 (30.11), 185.1173 (69.58), 137.0952 (3.28), 121.0645 (81.36), 97.0644 (54.92) | 23.61 | 0.057 | 1, 2, 3 |
| 31 | 9,10-dihydroxy-octadecanoic acid | C18H36O4 | 315.2542 | 315.2542 (100), 297.2441 (2.49), 245.1134 (1.23), 141.1274 (1.74) | 27.55 | 0.498 | 2, 3, 4 |
| 32 | 9,10,13-trihydroxy-11,15-octadecadienoic acid | C18H32O5 | 327.2179 | 327.2179 (100), 291.1970 (4.22), 229.1444 (11.72), 211.1335 (11.95), 171.1019 (17.29), 137.0964 (1.66), 97.0644 (1.76), 85.0279 (5.99), 57.0331 (1.61) | 19.76 | 0.711 | 1, 2, 3, 4 |
| 33 | 9,12,13-trihydroxy-10,15-octadecadienoic acid | C18H32O5 | 327.2179 | 327.2179 (100), 309.2075 (0.88), 291.1970 (3.35), 229.1442 (9.90), 171.1016 (19.90), 137.0960 (2.44), 97.0644 (2.13), 85.0280 (8.19) | 20.41 | 0.497 | 1, 2, 3 |
| 34 | 9,10,15-trihydroxy-12,15-octadecadienoic acid | C18H32O5 | 327.2178 | 327.2178 (100), 291.1971 (4.03), 239.1646 (13.19), 211.1326 (3.22), 197.1174 (25.96) | 22.05 | 1.628 | 2, 4 |
| 35 | 11,12,15-trihydroxy-9,12-octadecadienoic acid | C18H32O5 | 327.2177 | 327.2177 (100), 309.2074 (4.59), 197.1174 (32.96), 183.0113 (21.35), 111.0803 (9.25) | 22.90 | 0.039 | 2, 4 |
|
| |||||||
| 36 | heptanol pentosyl-hexoside | C18H34O10 | 409.2081 | 409.2081 (100), 277.1660 (30.60), 233.0650 (1.43), 161.0438 (9.50), 131.0335 (12.33), 113.0228 (11.04), 101.0228 (32.73), 89.0229 (15.08), 71.0122 (39.57) | 12.82 | 0.512 | 2 |
| 37 | ursolic acid hexuronyl-hexoside | C42H66O14 | 793.4395 | 793.4395 (100), 631.3859 (10.19), 569.3862 (7.64), 455.3518 (2.06), 316.2431 (0.52), 175.0233 (0.71), 157.0130 (0.74), 113.0231 (8.27), 85.0280 (17.25) | 2323 | 1.929 | 1, 2, 3, 4 |
a compared to reference standard; 1-Ethyl acetate extract; 2-MeOH extract; 3-Dichloromethane extract; 4-Infusion with water.
Figure 4Antioxidant properties of the tested extracts and their correlation with TPC and TFC. TE: Trolox equivalent; EDTAE: EDTA equivalent. a–d bar wise values with same superscripts of this type indicate no significant difference among extracts (p > 0.05).
Figure 5Venn diagram showing number of common compounds in the tested extracts.
Figure 6Enzyme inhibitory properties of the tested extracts and their correlation with TPC and TFC. GALAE: Galatamine equivalent; KAE: Kojic acid equivalent; ACAE: Acarbose equivalent. a–d bar wise values with same superscripts of this type indicate no significant difference among extracts (p > 0.05).
Figure 7(A–C): Principal Component Analysis; (A) Eigenvalue and Percentage of variability explained by each dimensions. (B) circle of correlation showing the relation between the bioactivities and Dim 1, Dim 2. (C) Scatter plots displaying the distribution of solvents on the factorial plan Dim 1 vs. Dim 2. (D) Heatmap showing bioactivities variation between the solvents.
Figure 8Anticancer activity of methanol and water extracts of B. diffusa on MDA-MB-231 breast cancer cells. Cell survival rates after 24 h and 48 h treatment by methanolic (A) and water (B) extracts. IC50 values of the methanolic extract after 24 h and 48 h treatments (C). Representative images for the morphological appearance of the treated cells (D). Data represent the means ± SD (n = 3). The scale bar is 100 µm.